The stock of Mersana Therapeutics Inc (MRSN) has seen a -14.30% decrease in the past week, with a -2.36% drop in the past month, and a -77.19% decrease in the past quarter. The volatility ratio for the week is 9.66%, and the volatility levels for the past 30 days are at 14.13% for MRSN. The simple moving average for the last 20 days is -3.62% for MRSN’s stock, with a simple moving average of -67.62% for the last 200 days.
Is It Worth Investing in Mersana Therapeutics Inc (NASDAQ: MRSN) Right Now?
Company’s 36-month beta value is 1.63.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MRSN is 86.40M, and currently, short sellers hold a 10.96% ratio of that floaft. The average trading volume of MRSN on February 18, 2025 was 4.67M shares.
MRSN) stock’s latest price update
Mersana Therapeutics Inc (NASDAQ: MRSN)’s stock price has gone rise by 3.08 in comparison to its previous close of 0.58, however, the company has experienced a -14.30% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-02-07 that CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on February 3, 2025, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 20,610 shares of its common stock, to one new employee whose employment commenced in January 2025. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
Analysts’ Opinion of MRSN
Citigroup, on the other hand, stated in their research note that they expect to see MRSN reach a price target of $5. The rating they have provided for MRSN stocks is “Buy” according to the report published on November 15th, 2024.
JP Morgan gave a rating of “Neutral” to MRSN, setting the target price at $5 in the report published on March 19th of the previous year.
MRSN Trading at -50.38% from the 50-Day Moving Average
After a stumble in the market that brought MRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.45% of loss for the given period.
Volatility was left at 14.13%, however, over the last 30 days, the volatility rate increased by 9.66%, as shares sank -2.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -74.68% lower at present.
During the last 5 trading sessions, MRSN fell by -14.27%, which changed the moving average for the period of 200-days by -81.07% in comparison to the 20-day moving average, which settled at $0.6224. In addition, Mersana Therapeutics Inc saw -58.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRSN starting from Mandelia Ashish, who sale 3,554 shares at the price of $0.58 back on Jan 16 ’25. After this action, Mandelia Ashish now owns 57,519 shares of Mersana Therapeutics Inc, valued at $2,061 using the latest closing price.
Protopapas Anna, the Director of Mersana Therapeutics Inc, sale 8,637 shares at $0.58 during a trade that took place back on Jan 16 ’25, which means that Protopapas Anna is holding 168,041 shares at $5,009 based on the most recent closing price.
Stock Fundamentals for MRSN
Current profitability levels for the company are sitting at:
- -2.28 for the present operating margin
- 0.48 for the gross margin
The net margin for Mersana Therapeutics Inc stands at -2.14. The total capital return value is set at -0.78. Equity return is now at value -280.29, with -34.51 for asset returns.
Based on Mersana Therapeutics Inc (MRSN), the company’s capital structure generated 0.97 points at debt to capital in total, while cash flow to debt ratio is standing at -3.09. The debt to equity ratio resting at 30.03. The interest coverage ratio of the stock is -19.77.
Currently, EBITDA for the company is -166.08 million with net debt to EBITDA at 0.67. When we switch over and look at the enterprise to sales, we see a ratio of 0.77. The receivables turnover for the company is 34.84for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
In a nutshell, Mersana Therapeutics Inc (MRSN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
